Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • CJASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • JASN Podcasts
    • Article Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
  • Editorial Fellowship
    • Editorial Fellowship Team
    • Editorial Fellowship Application Process
  • More
    • About JASN
    • Advertising
    • Alerts
    • Feedback
    • Impact Factor
    • Reprints
    • Subscriptions
  • ASN Kidney News
  • Follow JASN on Twitter
  • Visit ASN on Facebook
  • Follow JASN on RSS
  • Community Forum
Up Front MattersEditorials
You have accessRestricted Access

The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression

Yumeng Wen and Chirag R. Parikh
JASN January 2021, 32 (1) 2-4; DOI: https://doi.org/10.1681/ASN.2020091317
Yumeng Wen
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yumeng Wen
Chirag R. Parikh
Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chirag R. Parikh
  • Article
  • Info & Metrics
  • View PDF
Loading
  • diabetes mellitus
  • acute kidney injury
  • acute kidney disease
  • chronic kidney disease

AKI and CKD are interconnected syndromes with significant long-term sequelae such as progressive CKD, cardiovascular events, and death.1,2 Diabetes is not only a major cause of CKD, but is also an independent risk factor for AKI. AKI in diabetic patients is associated with medications such as renin-angiotensin system (RAS) blockade agents, sodium-glucose cotransporter-2 inhibitors, and shared risk factors such as hypertension and cardiovascular diseases.3 However, the actual estimates of AKI incidence in diabetic patients remains imprecise because most epidemiologic studies are on the basis of administrative codes rather than laboratory measurements of change in serum creatinine.4

In this issue, Hapca et al.5 investigated risk of AKI and the relationship between AKI occurrence and subsequent CKD progression in patients with diabetes. They utilized an observational cohort study, enrolling >18,000 Scottish participants with longitudinal data linked to local health care records and registry, and compared the incidence of AKI, subsequent decline in eGFR, and CKD progression in diabetic patients who were adequately matched with nondiabetic controls. They developed a novel algorithm to identify AKI episodes with the addition of serum creatinine up to 1 year after discharge. This approach facilitated the determination of the duration of the AKI episode and whether AKI progressed to acute kidney disease (AKD). However, a major limitation in such kidney registry studies is using creatinine both in the definition of exposure (AKI) and outcome (eGFR for development of CKD). In addition, the rate at which renal function worsens may not necessarily be quick enough to meet the definition of AKI but may rather manifest as AKD followed by continuous worsening of renal function to meet the definition of CKD. Also, AKI episodes in diabetic patients may require a prolonged recovery time with persistently elevated creatinine level before progression to CKD. With availability of longitudinal creatinine values, the authors were careful about misclassifying recurrent AKI and AKD states, after initial AKI episodes, as occurrence of CKD. The inclusion of post-AKI creatinine increased the detection of AKI from 28,306 to 40,567 cases. During the 8-year follow-up, patients with diabetes were almost five times more likely to experience AKI and more recurrent AKI than nondiabetic controls (121 versus 25 per 1000 person-years, adjusted rate ratio 4.7, 95% confidence interval 4.4 to 5.5), and those who had diabetes and CKD at baseline were two times more likely to experience AKI and more recurrent AKI compared with nondiabetic CKD controls (adjusted rate ratio 2.1, 95% confidence interval 2.1 to 2.5). However, there was no difference in the severity and duration of AKI between diabetic versus nondiabetic groups. Patients in both diabetic and nondiabetic groups who developed AKI had steeper eGFR declines before AKI episodes than those who did not develop AKI, although the decline was much more prominent in diabetic patients (slope pre-AKI versus no AKI −1.14 in diabetic group and −0.29 in nondiabetic group). Furthermore, AKI accentuated eGFR decline in both groups, and the effect was more prominent and statistically significant in nondiabetic patients (slope post-AKI versus pre-AKI −0.29 in diabetic group and −0.55 in nondiabetic group). The increased risk of kidney disease progression in diabetic patients after AKI episodes was similarly seen in the landmark Assessment, Serial Evaluation, and Subsequent Sequelae in AKI cohort in which patients had lower eGFR at baseline and were recruited in the acute hospital setting.6

As the authors discuss, the higher risks of AKI in diabetic patients may be associated with preexisting subclinical injury, such as glomerulosclerosis, interstitial inflammation, fibrosis, and compensatory glomerular hyperfiltration, either from diabetes or a higher burden of comorbidities.7 More importantly, the study highlights the effect of AKI on eGFR decline in both diabetic and nondiabetic patients. The casual relationship of AKI and the development of CKD is well established in epidemiologic studies.2 In addition to eGFR, the presence of microalbuminuria after AKI is strongly predictive of transition to CKD and CKD progression.6 Multiple pathophysiologic pathways have been studied extensively to solve the conundrum of AKI to CKD transition. Inflammation, microvascular rarefaction, mitochondrial dysfunction, and cell senescence could eventually lead to maladaptive repair, tubular atrophy, and interstitial fibrosis.8 Therefore, it is not surprising that the urinary kidney injury molecule-1, TNF receptor-1, and basic fibroblast growth factor were shown to predict incident CKD or CKD progression in patients who developed AKI after cardiac surgery.9 In addition, persistent activation of the intrinsic RAS after prolonged ischemia was found to correlate with interstitial fibrosis in mice models and CKD progression in a small group of patients with acute tubular injury.10 Although RAS blockade or sodium-glucose cotransporter-2 inhibitor may decrease albuminuria, counteract overactive RAS, and provide long-term kidney benefit, the use of these therapies after AKI episodes may also increase the risk of recurrent AKI via hemodynamic changes. These episodes of recurrent AKI require careful scrutiny to minimize discontinuation of these renoprotective medications. However, these two important medications are not evaluated in this study and deserve further investigation.

This study demonstrated a robust approach to improve the detection of AKI in future large-scale epidemiologic research involving registries with serial measurements of kidney function. Although this algorithm does not allow early detection and prevention of AKI, this approach would assist future research in large cohorts or electronic health records to understand different AKI and AKD phenotypes, and thus fill the clinical gap of events leading to CKD. However, we do need to interpret this study with caution as comorbidities, the use of RAS blockade, and microalbuminuria are not adjusted and may attenuate the high risk ratio for AKI seen in diabetic patients. Additional analysis on how different stages or durations of AKI may affect long-term eGFR decline would also enrich existing knowledge. It is unclear whether these AKI episodes truly reflect intrinsic kidney injury or simply reflect fluctuations of serum creatinine during initiation or titration of certain medications, such as RAS blockade and diuretics, which are both commonly used in diabetic patients. In addition, diabetic patients underwent more frequent creatinine measurement, making it more likely for AKI to be captured, compared with nondiabetic patients, although sensitivity analysis comparing stage 2 and 3 AKI in diabetic and nondiabetic patients revealed similar results.

Prospective studies and clinical trials are needed to address these limitations, and to improve our knowledge of AKI events in diabetes and our approaches to reduce AKI to CKD transition. The National Institute of Diabetes and Digestive and Kidney Diseases has prioritized research in this area and will support multicenter consortium to conduct interventional trials to improve post-AKI care.11 Prospective clinical trials could follow patients after hospitalization for AKI, use biomarkers to identify high-risk patients for CKD progression, and eventually explore the benefits of several interventions in these high-risk patients.

Disclosures

C. Parikh is a member of the advisory board of RenalytixAI and owns equity in the same. He also serves as a data safety and monitoring board member for Genfit. The remaining author has nothing to disclose.

Funding

C. Parikh was supported by National Institutes of Health grants R01DK-93770 and R01HL-085757, and is also participating in the National Institute of Diabetes and Digestive and Kidney Diseases-sponsored Kidney Precision Medicine Project UH3DK114866.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or JASN. Responsibility for the information and views expressed herein lies entirely with the authors.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

  • See related article, “The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study,” on pages 138–150.

  • Copyright © 2021 by the American Society of Nephrology

Reference

  1. ↵
    1. Hsu CY,
    2. McCulloch CE,
    3. Fan D,
    4. Ordoñez JD,
    5. Chertow GM,
    6. Go AS
    : Community-based incidence of acute renal failure. Kidney Int 72: 208–212, 2007 pmid:17507907
    OpenUrlCrossRefPubMed
  2. ↵
    1. Coca SG,
    2. Singanamala S,
    3. Parikh CR
    : Chronic kidney disease after acute kidney injury: A systematic review and meta-analysis. Kidney Int 81: 442–448, 2012 pmid:22113526
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bell S,
    2. Dekker FW,
    3. Vadiveloo T,
    4. Marwick C,
    5. Deshmukh H,
    6. Donnan PT, et al
    .: Risk of postoperative acute kidney injury in patients undergoing orthopaedic surgery--development and validation of a risk score and effect of acute kidney injury on survival: Observational cohort study. BMJ 351: h5639, 2015 pmid:26561522
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Peerapornratana S,
    2. Manrique-Caballero CL,
    3. Gómez H,
    4. Kellum JA
    : Acute kidney injury from sepsis: Current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int 96: 1083–1099, 2019 pmid:31443997
    OpenUrlCrossRefPubMed
  5. ↵
    1. Hapca S,
    2. Siddiqui M,
    3. Kwan R,
    4. Lim M,
    5. Matthew S,
    6. Doney ASF, et al
    .; BEAt-DKD Consortium: The relationship between AKI and CKD in patients with type 2 diabetes: An observational cohort study [published online ahead of print Sep 18, 2020]. J Am Soc Nephrol 32: 138–150, 2021
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Hsu C-Y,
    2. Chinchilli VM,
    3. Coca S,
    4. Devarajan P,
    5. Ghahramani N,
    6. Go AS, et al
    .; ASSESS-AKI Investigators: Post-acute kidney injury proteinuria and subsequent kidney disease progression: The Assessment, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury (ASSESS-AKI) study. JAMA Intern Med 180: 402–410, 2020 pmid:31985750
    OpenUrlPubMed
  7. ↵
    1. Zhang WR,
    2. Parikh CR
    : Biomarkers of acute and chronic kidney disease. Annu Rev Physiol 81: 309–333, 2019 pmid:30742783
    OpenUrlCrossRefPubMed
  8. ↵
    1. Zuk A,
    2. Bonventre JV
    : Acute kidney injury. Annu Rev Med 67: 293–307, 2016 pmid:26768243
    OpenUrlCrossRefPubMed
  9. ↵
    1. Menez S,
    2. Moledina DG,
    3. Garg AX,
    4. Thiessen-Philbrook H,
    5. McArthur E,
    6. Jia Y, et al
    .: Results from the TRIBE-AKI Study found associations between post-operative blood biomarkers and risk of chronic kidney disease after cardiac surgery [published online ahead of print Jul 25, 2020]. Kidney Int doi:10.1016/j.kint.2020.06.037 pmid:32721447
    OpenUrlCrossRefPubMed
  10. ↵
    1. Cui S,
    2. Wu L,
    3. Feng X,
    4. Su H,
    5. Zhou Z,
    6. Luo W, et al
    .: Urinary angiotensinogen predicts progressive chronic kidney disease after an episode of experimental acute kidney injury. Clin Sci (Lond) 132: 2121–2133, 2018 doi:10.1042/CS20180758 pmid:30224346
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. National Institute of Diabetes and Digestive and Kidney Diseases
    : Caring for outPatiEnts after Acute Kidney Injury (COPE-AKI) – clinical centers (U01 Clinical Trial Required). Available at: https://www.niddk.nih.gov/research-funding/current-opportunities/rfa-dk-20-011. Accessed September 30, 2020
PreviousNext
Back to top

In this issue

Journal of the American Society of Nephrology: 32 (1)
Journal of the American Society of Nephrology
Vol. 32, Issue 1
January 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in JASN.
Enter multiple addresses on separate lines or separate them with commas.
The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
Yumeng Wen, Chirag R. Parikh
JASN Jan 2021, 32 (1) 2-4; DOI: 10.1681/ASN.2020091317

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
The Aftermath of AKI: Recurrent AKI, Acute Kidney Disease, and CKD Progression
Yumeng Wen, Chirag R. Parikh
JASN Jan 2021, 32 (1) 2-4; DOI: 10.1681/ASN.2020091317
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • Reference
  • Info & Metrics
  • View PDF

More in this TOC Section

Up Front Matters

  • Molecular Characterization of Membranous Nephropathy: Quo Vadis?
  • More than a Marker: Arginase-1 in Kidney Repair
  • Enabling Patient Choice: The “Deciding Not to Decide” Option for Older Adults Facing Dialysis Decisions
Show more Up Front Matters

Editorials

  • A Novel Pathological Mechanism of Tertiary Lymphoid Structure Formation in the Renal Pelvis
  • Disarming the Old Foe. Restoring T-Cell Immune Function with mTor-Inhibitors to Tackle Cytomegalovirus Infection
  • Genome-wide Admixture Mapping of eGFR and CKD Identify European and African Ancestry-of-Origin Loci in US Hispanics/Latinos
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study
  • PubMed
  • Google Scholar

Keywords

  • diabetes mellitus
  • acute kidney injury
  • acute kidney disease
  • chronic kidney disease

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Annual Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • Editorial Fellowship Program
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • JASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About JASN
  • JASN Email Alerts
  • JASN Key Impact Information
  • JASN Podcasts
  • JASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1046-6673 Online ISSN - 1533-3450

Powered by HighWire